Advanced search
Publication Cover
Global Health Action Volume 7, 2014 - Issue 1
Submit an article Journal homepage
723
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Experiences in anti-tuberculosis treatment in patients with multiple previous treatments and its impact on drug resistant tuberculosis epidemics

Biao XuDepartment of EpidemiologySchool of Public Health, Fudan University, Shanghai, China;Correspondence[email protected]
,
Qi ZhaoDepartment of EpidemiologySchool of Public Health, Fudan University, Shanghai, China;
,
Yi HuDepartment of EpidemiologySchool of Public Health, Fudan University, Shanghai, China;
,
Ying ShiDepartment of EpidemiologySchool of Public Health, Fudan University, Shanghai, China;;The Department of Tuberculosis Prevention and ControlMinistry of Health, Beijing, China;
,
Weibing WangDepartment of EpidemiologySchool of Public Health, Fudan University, Shanghai, China;
&
Vinod K. DiwanSchool of Public HealthCentre for Global Health, Karolinska Institutet, Stockholm, Sweden
Article: 24593 | Received 09 Apr 2014, Accepted 02 Jul 2014, Published online: 18 Aug 2014

References

  • WHO. Global tuberculosis control: WHO report 2011 (WHO/HTM/TB/2011.16). 2011; Geneva: WHO.
  • Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, etal. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366: 2161–70. [PubMed Abstract].
  • Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006; 81: 430–2.
  • Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006; 55: 301–5.
  • Marahatta SB. Multi-drug resistant tuberculosis burden and risk factors: an update. Kathmandu Univ Med J (KUMJ). 2010; 8: 116–25. [PubMed Abstract].
  • Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am. 2010; 24: 705–25. [PubMed Abstract].
  • Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal K, etal. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006; 12: 1389–97. [PubMed Abstract] [PubMed CentralFull Text].
  • World Health Organization. Multidrug and extensively drug-resistant tuberculosis (M/XDR-TB). 2010 global report on surveillance and response. 2010; Geneva, Switzerland: World Health Organization.
  • Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis . Proc Natl Acad Sci USA. 2009; 106: 14711–15. [PubMed Abstract] [PubMed CentralFull Text].
  • Cha J, Lee HY, Lee KS, Koh WJ, Kwon OJ, Yi CA, etal. Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol. 2009; 10: 207–16. [PubMed Abstract] [PubMed CentralFull Text].
  • Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res. 2012; 40: 436–45. [PubMed Abstract].
  • Vilarica AS, Gomes C, Pina J. Comparative analysis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis – epidemiology and predictive factors. Rev Port Pneumol. 2008; 14: 829–42. [PubMed Abstract].
  • Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009; 9: 169. [PubMed Abstract] [PubMed CentralFull Text].
  • Sun Q, Meng Q, Yip W, Yin X, Li H. DOT in rural China: experience from a case study in Shandong Province, China. Int J Tuberc Lung Dis. 2008; 12: 625–30. [PubMed Abstract].
  • Long Q, Li Y, Wang Y, Yue Y, Tang C, Tang S, etal. Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res. 2008; 8: 202. [PubMed Abstract] [PubMed CentralFull Text].
  • Wei X, Liang X, Liu F, Walley JD, Dong B. Decentralising tuberculosis services from county tuberculosis dispensaries to township hospitals in China: an intervention study. Int J Tuberc Lung Dis. 2008; 12: 538–47. [PubMed Abstract].
  • Yao S, Huang WH, van den Hof S, Yang SM, Wang XL, Chen W, etal. Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China. BMC Health Serv Res. 2011; 11: 341. [PubMed Abstract] [PubMed CentralFull Text].
  • Hu D, Liu X, Chen J, Wang Y, Wang T, Zeng W, etal. Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health Policy Plan. 2008; 23: 43–55. [PubMed Abstract].
  • Fanning A. For tuberculosis elimination, directly observed therapy, short course (DOTS) is essential but not sufficient. Int J Circumpolar Health. 2011; 70: 106–8. [PubMed Abstract].
  • Sharma SK, Liu JJ. Progress of DOTS in global tuberculosis control. Lancet. 2006; 367: 951–2. [PubMed Abstract].
  • Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008; 149: 123–34. [PubMed Abstract].
  • Bojorquez-Chapela I, Backer CE, Orejel I, Lopez A, Diaz-Quinonez A, Hernandez-Serrato MI, etal. Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis. Int J Tuberc Lung Dis. 2013; 17: 514–19. [PubMed Abstract].
  • He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, etal. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis. 2008; 8: 166. [PubMed Abstract] [PubMed CentralFull Text].
  • Ausina Ruiz V, Fernandez-Rivas G, Vilaplana Messeguer C. Selected culture and drug-susceptibility testing methods for drug-resistant Mycobacterium tuberculosis screening in resource-constrained settings. Expert Rev Mol Diagn. 2013; 13: 247–9. [PubMed Abstract].
  • Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, etal. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013; 13: 349–61. [PubMed Abstract].
  • Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, etal. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38: 516–28. [PubMed Abstract].
  • He GX, van den Hof S, Borgdorff MW, van der Werf MJ, Cheng SM, Hu YL, etal. Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis. Int J Tuberc Lung Dis. 2010; 14: 884–9. [PubMed Abstract].
  • Zhang G, Du C, Kurasawa T, Ikeda X, Wang W, Shi R, etal. China-Japan cooperation project on second-line tuberculosis drug resistance survey in Henan Province. J Med Forum. 2005; 26: 14–16.
  • Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, after the implementation of DOTS-plus, 1995–2002. Int J Tuberc Lung Dis. 2004; 8: 760–6. [PubMed Abstract].
  • Hu Y, Hoffner S, Wu L, Zhao Q, Jiang W, Xu B. Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China. Antimicrob Agents Chemother. 2013; 57: 3857–63. [PubMed Abstract] [PubMed CentralFull Text].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.